168 related articles for article (PubMed ID: 35054388)
1. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal.
Tsai HC; Ho KC; Chen SH; Tseng JR; Yang LY; Lin KJ; Cheng JC; Liou MJ
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054388
[TBL] [Abstract][Full Text] [Related]
2. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
4. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
[TBL] [Abstract][Full Text] [Related]
5. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for
Gomes-Lima CJ; Chittimoju S; Wehbeh L; Dia S; Pagadala P; Al-Jundi M; Jhawar S; Tefera E; Mete M; Klubo-Gwiezdzinska J; Van Nostrand D; Jonklaas J; Wartofsky L; Burman KD
J Endocr Soc; 2022 May; 6(5):bvac032. PubMed ID: 35356009
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
[No Abstract] [Full Text] [Related]
8. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine.
Mujammami M; Hier MP; Payne RJ; Rochon L; Tamilia M
Thyroid; 2016 Jul; 26(7):951-8. PubMed ID: 27150203
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
13. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.
Luo H; Tobey A; Auh S; Cochran C; Zemskova M; Reynolds J; Lima C; Burman K; Wartofsky L; Skarulis M; Kebebew E; Klubo-Gwiezdzinska J
Clin Endocrinol (Oxf); 2018 Oct; 89(4):481-488. PubMed ID: 29972703
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.
Sunavala-Dossabhoy G; Petti S
Oral Oncol; 2023 Jan; 136():106280. PubMed ID: 36525783
[TBL] [Abstract][Full Text] [Related]
16. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
Liepe K
Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]